NewsBenzingaEvercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $110 Evercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $110 Benzinga 2026.11.04 13:26 (GMT+0) Open on Benzinga Other news Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $135 CORRECTION: ECARX Holdings Q3 EPS $(0.13) Down From $(0.03) YoY, Sales $240.800M Miss $313.935M Estimate SpaceX Stock Dips: What's Going On? UPDATE: Ocugen Q3 Adj. EPS $(0.06), Inline, Sales $1.951M Beat $1.098M Estimate Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224 Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78
CORRECTION: ECARX Holdings Q3 EPS $(0.13) Down From $(0.03) YoY, Sales $240.800M Miss $313.935M Estimate
